Norges Bank Acquires New Position in Henry Schein, Inc. $HSIC

Norges Bank acquired a new stake in shares of Henry Schein, Inc. (NASDAQ:HSIC) during the fourth quarter, Holdings Channel.com reports. The fund acquired 1,165,867 shares of the company’s stock, valued at approximately $88,116,000.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in the stock. Eurizon Capital SGR S.p.A. purchased a new position in Henry Schein during the fourth quarter valued at approximately $1,946,000. Intech Investment Management LLC purchased a new position in Henry Schein during the fourth quarter valued at approximately $525,000. Clearstead Advisors LLC grew its position in Henry Schein by 70.7% during the fourth quarter. Clearstead Advisors LLC now owns 1,681 shares of the company’s stock valued at $127,000 after purchasing an additional 696 shares in the last quarter. Dilation Capital Management LP grew its position in Henry Schein by 3.3% during the fourth quarter. Dilation Capital Management LP now owns 79,465 shares of the company’s stock valued at $6,006,000 after purchasing an additional 2,545 shares in the last quarter. Finally, Swedbank AB grew its position in Henry Schein by 1.0% during the fourth quarter. Swedbank AB now owns 1,312,312 shares of the company’s stock valued at $99,185,000 after purchasing an additional 12,741 shares in the last quarter. 96.62% of the stock is owned by hedge funds and other institutional investors.

Henry Schein Price Performance

Shares of Henry Schein stock opened at $77.45 on Friday. The firm has a fifty day simple moving average of $74.70 and a 200-day simple moving average of $75.93. The company has a current ratio of 1.36, a quick ratio of 0.75 and a debt-to-equity ratio of 0.59. Henry Schein, Inc. has a 1-year low of $61.94 and a 1-year high of $89.29. The stock has a market capitalization of $8.82 billion, a price-to-earnings ratio of 23.40, a PEG ratio of 1.47 and a beta of 0.82.

Henry Schein (NASDAQ:HSIC) last issued its quarterly earnings data on Tuesday, May 5th. The company reported $1.32 earnings per share for the quarter, topping analysts’ consensus estimates of $1.20 by $0.12. Henry Schein had a net margin of 2.95% and a return on equity of 15.44%. The business had revenue of $3.37 billion during the quarter, compared to analysts’ expectations of $3.34 billion. During the same period in the previous year, the company earned $1.15 earnings per share. Henry Schein’s revenue for the quarter was up 6.3% on a year-over-year basis. Henry Schein has set its FY 2026 guidance at 5.230-5.370 EPS. On average, sell-side analysts expect that Henry Schein, Inc. will post 5.32 earnings per share for the current year.

Insider Transactions at Henry Schein

In other news, CEO Thomas C. Popeck sold 1,355 shares of the business’s stock in a transaction on Thursday, March 19th. The shares were sold at an average price of $72.79, for a total value of $98,630.45. Following the completion of the sale, the chief executive officer directly owned 86,182 shares in the company, valued at approximately $6,273,187.78. The trade was a 1.55% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Kurt P. Kuehn sold 2,844 shares of the business’s stock in a transaction on Tuesday, March 10th. The stock was sold at an average price of $78.96, for a total transaction of $224,562.24. Following the completion of the sale, the director owned 15,420 shares of the company’s stock, valued at $1,217,563.20. The trade was a 15.57% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. 0.89% of the stock is owned by corporate insiders.

Analyst Ratings Changes

A number of research analysts recently commented on the stock. Leerink Partners reaffirmed a “market perform” rating on shares of Henry Schein in a research report on Monday, March 9th. Morgan Stanley reissued an “underweight” rating and issued a $64.00 target price (up from $61.00) on shares of Henry Schein in a research report on Friday, April 24th. Citigroup started coverage on shares of Henry Schein in a research report on Wednesday, April 15th. They issued a “buy” rating and a $100.00 target price for the company. Weiss Ratings reissued a “hold (c+)” rating on shares of Henry Schein in a research report on Monday, May 4th. Finally, BTIG Research started coverage on shares of Henry Schein in a research report on Thursday, April 16th. They issued a “neutral” rating for the company. Six equities research analysts have rated the stock with a Buy rating, seven have issued a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average target price of $86.83.

About Henry Schein

Henry Schein, Inc is a leading global distributor of healthcare products and services, primarily serving office-based dental, medical and animal health practitioners. The company operates through three principal segments—Schein Dental, Schein Medical and Animal Health—each offering a comprehensive portfolio of consumable products, equipment, instruments and related value-added services. With a focus on improving practice efficiency and patient care, Henry Schein provides everything from dental restorative materials and orthodontic appliances to vaccines, pharmaceuticals and diagnostic devices for physicians, as well as pet health products and veterinary equipment for animal health professionals.

In addition to its broad product offering, Henry Schein delivers a suite of technology and service solutions aimed at streamlining workflows and enhancing clinical outcomes.